Antimalarial drugs: QT prolongation and cardiac arrhythmias

Bibliography

• CROFT AM, WHITEHOUSE, COOK GC, BEER D: Safety evaluation of the drugs available to prevent malaria. Expert Opin. Drug Sal (2002) 1(1):19–27.
   PubMedGoogle Scholar
• ••Detailed overview on all adverse eventsassociated with current antimalaria drugs.
   Google Scholar
• NOSTEN F, PRICE RN: New antimalarials: A risk benefit analysis. Drug Sal: (1995) 12:264–273.
   PubMed Web of Science ®Google Scholar
• TOUZE JE, HENO P, FOURCADE L et al.: The effects of antimalarial drugs on ventricular repolarization. Aim Trop. Med. Hyg. (2002) 67:54–60.
   PubMed Web of Science ®Google Scholar
• BELARDINELLI L, ANTZELEVITCH C, VOS MA: Assessing predictors ofdrug-induced torsade de pointes. Trends.Pharmacol Sci. (2003) 24 (1 2) :619–625.
   Google Scholar
• ••Excellent review on dispersion oftransmural repolarisation and its Interpretation.
   Google Scholar
• ENGEL G, BECKERMAN JG,FROELICHER et al.: Electrocardiographic arrhythmia risk testing. Corr. Pro& Cardiol(2004) 29(7):365–432.
   Google Scholar
• SANGUINETTI MC, JURKIEWICZ NK: Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physic] (1990) 96:195–215.
   Google Scholar
• SANGUINETTI MC, JIANG C, CURRAN ME, KEATING MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERGencodes the IKr potassium channel. Cell (1995) 81:299–307.
   PubMed Web of Science ®Google Scholar
• •First proof that hERG channels are involved in arrhythmias.
   Google Scholar
• KANG J, CHEN XL, WANG L, RAMPE D: Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. I Pharmacol Exp. Ther. (2001) 299(1):290–296.
   PubMed Web of Science ®Google Scholar
• WANG Q, CURRAN ME, SPLAWSKI I et al.: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. (1996) 12(1):17–23.
   PubMed Web of Science ®Google Scholar
• CRUMP W, CAVERO I: QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drugdevelopment. Pharm. Li. Tech. Today (1999) 2:270–280.
   PubMedGoogle Scholar
• REDFERN WS, CARLSSON L, DAVIS AS et al.: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. (2003) 58:32–45.
   PubMed Web of Science ®Google Scholar
• ••First publication on safety margins incardiac safety pharmacology.
   Google Scholar
• WARMKE JW, GANETZKY B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Nati Acad. Sri. USA (1994) 91(8):3438–3442.
   PubMed Web of Science ®Google Scholar
• LEE K, PARK JY, RYU PD, KWON LS, KIM HY: Ilcr channel blockers: novel antiarrhythmic agents. Curr. Med. Chem. Cardiovasc. Hematol. Agents(2003) 1(3):203–223.
   PubMedGoogle Scholar
• RAMPED, ROY ML, DENNIS A, BROWN AM: A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. (1997) 3; 417(1):28–32.
   Google Scholar
• SPECTOR PS, CURRAN ME, KEATING MT, SANGUINETTI MC: Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Circ. Res. (1996) 78:499–503.
   Google Scholar
• ZHOU Z, VORPERIAN VR, GONG Q, ZHANG S, JANUARY CT: Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Cardiovasc. Electrophysiol. (1999) 10:836–843.
   PubMed Web of Science ®Google Scholar
• RAMPE D, MURAWSKY MK, GRAU J, LEWIS EW: The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. I Pharmacol. Exp. Ther. (1998) 286:788–793.
   PubMed Web of Science ®Google Scholar
• DROLET B, VINCENT F, RAIL J et al.:Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier Kt current. Pharmacol. Exp. Ther. (1999) 288:1261–1268.
   PubMed Web of Science ®Google Scholar
• KANG J, WANG L, CAI F, RAMPED: High affinity blockade of the HERG cardiac K(-t) channel by the neuroleptic pimozide. Eur.j Pharmacol. (2000) 392:137–140.
   PubMed Web of Science ®Google Scholar
• WEBSTER R, LEISHMANN D, WALKER D: Towards a drug concentration effect relationship for QT prolongation and torsades des pointes. Curr. Opin. Drug. Discov. Bevel. (2002) 5:116–126.
   PubMed Web of Science ®Google Scholar
• HANCOX JC, LEVI AJ, WITCHEL HJ: Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential. PlIugers Arch. (1998) 436(6):843–853.
   PubMed Web of Science ®Google Scholar
• WEMPE MF: Quaternary ammonium ions can externally block voltage-gated Kt channels. Establishing a theoretical and experimental model that predicts KDs and the selectivity of Kt over Na* ions. J. Mol. Struct. (2001) 562:63–78.
   Google Scholar
• CAVALLI A, POLUZZI E, DE PONTI F, RECANATINI M: Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. (2002)45:3844–3853.
   PubMed Web of Science ®Google Scholar
• •First attempt of creating a phamnacopohore for hERG channel interaction.
   Google Scholar
• ROCHE 0, TRUBE G, ZUEGGE J, PFLIMLIN P, ALANINE A, SCHNEIDER G: A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem. (2002) 3:455–459.
   PubMed Web of Science ®Google Scholar
• FICKER E, KURYSHEV YA, DENNIS AT et al.: Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. (2004) 66(1):33–44.
   PubMed Web of Science ®Google Scholar
• KURYSHEW YA, FICKER E, WANG L et al.: Pentamidine-induced long QT syndrome and block of hERG trafficking. Pharmacol. Exp. Ther. (2005) 312(1):316–323.
   PubMed Web of Science ®Google Scholar
• FERMINI B, FOSSA AA: The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev Drug. Discov. (2003) 2(6):439–447.
   PubMed Web of Science ®Google Scholar
• •Connects scientific and industrial interests.
   Google Scholar
• GUSSAK I, LITWIN J, KLEIMAN R, GRISANTI S, MORGANROTH J: Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug development.Electrocardiol. (2004) 37(1):19–24.
   PubMed Web of Science ®Google Scholar
• LOU S, MICHLER K, JOHNSTON P, MACFARLANE PW: A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc ofnormal ECGs. I Electrocardiol. (2004) 37:81–90.
   PubMed Web of Science ®Google Scholar
• LUO CH, RUDY Y: A dynamic model of the ventricular cardiac action potential.I. Simulations of ionic currents and concentration changes. Circ. Res. (1994) 74:1071–1096.
   Google Scholar
• VOLDERS PG, STENGL M,VAN OPSTAL JM et al.: Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc. Res. (2000) 46:376–392.
   Google Scholar
• MILBERG P MILBERG P, ECKARDT L, BRUNS HJ et al.: Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast Phase III repolarization prevents early afterdepolarizations and torsade de pointes. I Pharmacol. Exp. Ther.(2002) 303:218–225.
   PubMed Web of Science ®Google Scholar
• SHAH RR: The significance of QT interval in drug development. BE I Chi'. Pharmacol. (2002) 54(2):188–202.
   PubMed Web of Science ®Google Scholar
• YAN GX, WU Y, LIU T, WANG J, MARINCHAK RA, KOWEY PR: Phase II early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome. Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation (2001) 103:2851–2856.
   Google Scholar
• SURAWICZ B: Contributions of cellular electrophysiology to the understanding of the electrocardiogram. Experientia (1987) 43:1061–1068.
   PubMedGoogle Scholar
• LUO CH, RUDY Y: A model of the cardiacventricular action potential: depolarization, repolarization, and their interaction. Circ. Res. (1991) 68:1501–1526.
   PubMed Web of Science ®Google Scholar
• HONDEGHEM LM, DUJARDIN K, DE CLERCK F: Phase II prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. (2001) 50:345–353.
   PubMed Web of Science ®Google Scholar
• HONDEGHEM LM, CARLSSON L, DUKER G: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 103:2004–2013.
   PubMed Web of Science ®Google Scholar
• ••First report on the TRIad' concept forproarrhythmic drugs.
   Google Scholar
• HONDEGHEM LM, HOFFMANN P: Blinded test in isolated female rabbit heart reliably identifies action potential duration,prolongation, and proarrhythemic drugs: importance of triangulation, reverse use dependence, and instability. I Cardiovasc. Pharmacol (2003) 41:14–24.
   PubMed Web of Science ®Google Scholar
• VOS MA, VAN OPSTAL JM, LEUNISSEN JD, VERDUYN SC: Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsades de Pointes arrhythmias. Pharmacol Ther.(2001) 92:109–122.
   PubMed Web of Science ®Google Scholar
• SICOURI S, ANTZELEVITCH C: Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells(M cells) in the canine heart: quinidine and digitalis. I Cardiovasc. Electrophysiol (1993) 4:48–58.
   PubMed Web of Science ®Google Scholar
• JANUARY CT, RIDDLE JM: Early afterdepolarizations: mechanism of induction and block: a role for L-type Ca2' current. Circ. Res. (1989) 64:977–990.
   PubMed Web of Science ®Google Scholar
• EL-SHERIF N, CAREF EB, YIN H, RESTIVO M: The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ. Res. (1996) 79:474–492.
   PubMed Web of Science ®Google Scholar
• YAN GX, ANTZELEVITCH C: Cellular basis for the normal T wave and the electrocardiographic manifestations of the long QT syndrome. Circulation (1998) 98:1928–1936.
   PubMed Web of Science ®Google Scholar
• ANTZELEVITCH C, SHIMIZU W, YAN GX et al.: The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart.Cardiovasc. Electrophysiol (1999) 10:1124–1152.
   PubMed Web of Science ®Google Scholar
• ANTZELEVITCH C, SHIMIZU W: Cellular mechanisms underlying long QT syndrome. Curr. Opin. Cardiol (2002) 17:43–51.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on dispersion oftransmural repolarisation.
   Google Scholar
• DUMAINE R, ANTZELEVITCH C: Electrical heterogeneity in the heart: physiological, pharmacological, and clinical implications. In Handbook of Physiology (Fozzard, Solaro), Oxford University Press (2002):654–692.
   Google Scholar
• AKAR FG, LAURITA KR, ROSENBAUM DS: Cellular basis for dispersion of repolarization underlying reentrant arrhythmias. I Electrocardiol (2000) 33:23–31.
   PubMed Web of Science ®Google Scholar
• CURTIS LH, OSTBYE T,SENDERSKY V et al.: Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am. I Med. (2003) 114:135–141.
   Google Scholar
• HAVERKAMP W, BREITHARDT G, CAMM AJ et al.: The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovasc. Res. (2000) 47:219–233.
   Google Scholar
• VOS MA: Do we understand the electrophysiological mechanisms responsible for drug-induced cardiac arrhythmias?. Cardiovasc. Pharmacol (2002) 40:647–650.
   PubMed Web of Science ®Google Scholar
• BODE G, OLEJNICZAK K: ICH topic: the draft ICH 57B step 2: note for guidance on safety pharmacology studies for human pharmaceuticals. Fundam. Clin. Pharmacol (2002) 16(2):105–118.
   PubMed Web of Science ®Google Scholar
• LIGHTBOWN ID, LAMPERT JP, EDWARDS G, COKER SJ: Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine. BL J. Pharmacol. (2001) 132(1):197–204.
   PubMed Web of Science ®Google Scholar
• JONG EC, NOTHDURFT HD: Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety. J. Travel Med. (2001) 8(3):48–56.
   Google Scholar
• THYBO S, GJORUP I, RONN AM, MEYROWITSCH D, BYGBERG IC: Atovaquone-proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. J. Travel Med. (2004) 11(4):220–223.
   PubMed Web of Science ®Google Scholar
• KNOBLOCH JU: Long-term malaria prophylaxis for travelers. J. Travel Med. (2004) 11(6):374–378.
   PubMed Web of Science ®Google Scholar
• PETERSEN E: Malaria chemoprophylaxis: when should we use it and what are the options?. Expert Rev Anti. Infect. Ther. (2004) 2(1):119–132.
   PubMedGoogle Scholar
• WARHURST DC: Antimalarial drugs. An update. Drugs (1987) 33(1):50–65.
   Google Scholar
• COKER SJ, BATEY AJ,LIGHTB OWN ID, DIAZ ME, EISNER DA: Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes. BL J. Pharmacol (2000) 129(2):323–330.
   PubMed Web of Science ®Google Scholar
• GRIBBLE FM, DAVIS TM,HIGHAM CE, CLARK A,ASHCROFT FM: The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. BL J. Pharmacol (2000) 131(4):756–760.
   PubMed Web of Science ®Google Scholar
• FONTEYNE W, BAUWENS A, JORDAENS L: Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine.Cardiol (1996) 19(12):967–968.
   Web of Science ®Google Scholar
• LAOTHAVORN P, KARBWANG J, NA BANGCHANG K, BUNNAG D, HARINASUTA T: Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. Southeast. Asian. I Trop. Med. Public Health. (1992) 23(1):51–54.
   PubMedGoogle Scholar
• MORANT J, RUPPANER H: Swiss Compendium of Medidne 22nd Ed. Documed AG, Basel (2003).
   Google Scholar
• BAIRD JK, HOFFMAN SL: Primaquine therapy for malaria. Clin. Infect. Dis. (2004) 39(9):1336–1345.
   PubMed Web of Science ®Google Scholar
• WEERASINGHE KL,GALAPPATHTHY G, FERNANDO WP, WICKREMASINGHE DR, FAIZAL HM, WICKREMASINGHE AR: A safety and efficacy trial of artesunate, sulphadoxine-pyrimethamine and primaquine in P fakiparum malaria. Ceylon. Med. (2002) 47(3):83–85.
   PubMedGoogle Scholar
• BAIRD JK, RIECKMANN KH: Can primaquine therapy for vivax malaria be improved? Trends Pajsitol. (2003) 19(3):115–120.
   Google Scholar
• SLATER AF: Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther. (1993) 57(2-3):203–235.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-CHAPULA JA, NAVARRO-POLANCO RA, CULBERSON C, CHEN J, SANGUINETTI MC: Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. I Biol. Chem. (2002) 277(26):23587–23595.
   Web of Science ®Google Scholar
• TRAEBERT M, DUMOTIER B, MEISTER L, HOFFMANN P, DOMINGUEZ-ESTEVEZ M, SUTER W: Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur. Pharmacol (2004) 484(1):41–48.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-CHAPULA JA, SALINAS-STEFANON E, TORRES-JACOME J,
   Google Scholar